Skip to content

Natural Compound Curcumin as a Novel Therapy for Congestive Heart Failure: Effects of Curcumin on Left Ventricular Diastolic Function in Hypertensive Heart Disease

Natural Compound Curcumin as a Novel Therapy for Congestive Heart Failure: Effects of Curcumin on Left Ventricular Diastolic Function in Hypertensive Heart Disease - Curcumin for Hypertensive Heart Disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002098
Enrollment
100
Registered
2009-07-31
Start date
2009-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Heart Disease

Interventions

Curcumin 2g/day p.o. Placebo 2g/day p.o.

Sponsors

National Hospital Organization Kyoto Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Stable hypertensive patients: blood pressure =< 140/90 mmHg for a month or more 2) Hypertensive patients with left ventricular (LV) hypertrophy: past history of blood pressure >= 135/85 mmHg, and LV intraventricular septum thickness >= 11mm and/or LV posterior wall thickness >= 11mm, and LV ejection fraction >= 50% by echocardiograhy

Exclusion criteria

Exclusion criteria: 1) Chronic atrial fibrillation 2) Unstable angina, recent (< 3 months) myocardial infarction, severe coronary heart disease (left main trunk or 3 vessel disease), and recent (=< 3 months) or planned (=< 6 months) AC bypass surgery / PCI 3) Severe arrhythmia (sustained ventricular tachycardia, ventricular fibrillation, and severe bradycardia with an indication of pacemaker implantation 4) Moderate or severe valvular diseases 5) Cardiomyopathy or progressive myocarditis 6) Severe respiratory diseases 7) Cardiogenic shock or systolic blood pressure < 80 mmHg 8) Renal failure (Cre >= 4.0 mg/dL or dialysis) 9) Severe liver dysfunction or liver cirrhosis 10) Recent (< 3 months) cerebrovascular disease 11) Malignancy 12) Poorly controlled diabetes (HbA1c >= 8.0%) 13) Anemia (Hb < 6.0 mg/dL) 14) Use of steroid 15) Past history of Curcumin allergy 16) Pregnancy, nursing, or a wish for pregnancy within 6 months 17) etc

Design outcomes

Primary

MeasureTime frame
Conventional Doppler indices of left ventricular diastolic function including 1) Transmitral E/A ratio, 2) Decerelation time, 3) Pulmonary venous S/D ratio, etc Tissue Doppler indices of left ventricular diastolic function including 4) E/E' ratio, etc

Secondary

MeasureTime frame
1) Symptons 2) Activity (Mets) 3) Blood pressure, pulse rate, and body mass index 4) Blood analysis including BNP concentration and urinalysis 5) Plasma Curcumin concentration 6) Chest X-p 7) Electrocardiogram 8) Echocardiography: left ventricular (LV) end-diastolic dimension, LV end-systolic demension, LV ejection fraction, left atrial demension, intraventricular septum thickness, LV posterior wall thickness, transmitral E and A wave velosity, pulmonary S and D wave velosity, and tissue Doppler early diastolic mitral annular velosity, etc

Countries

Japan

Contacts

Public ContactKoji Hasegawa

National Hospital Organization Kyoto Medical Center Division of Translational Research

koj@kuhp.kyoto-u.ac.jp075-641-9161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026